Daiichi Sankyo Company, Limited announced that it has submitted a New Drug Application to Japan’s Ministry of Health, Labour and Welfare for valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, for the treatment of patients with relapsed/refractory adult T cell leukemia/lymphoma.
[Daiichi Sankyo Company, Limited]
Sorry, but the selected Zotpress account can't be found.
